Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualizing NSAIDs in Axial Spondyloarthritis
NCT04115098Phase 2Terminated
- Sponsor
- UTHealth Houston
- Start
- Jun 2020
- Primary completion
- Aug 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of celecoxib, meloxicam and naproxen in axial spondyloarthritis (axSpA) (12 arms), sponsored by UTHealth Houston. Primary endpoint: Ankylosing Spondylitis Disease Activity Score at 4 weeks. Started Jun 2020; status: terminated.
02
Drugs
celecoxibmeloxicamnaproxen
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT04115098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04115098.